logo
26 Dinosaur Facts That Are So Absolutely Bonkers I'm Questioning My Entire Education Right Now

26 Dinosaur Facts That Are So Absolutely Bonkers I'm Questioning My Entire Education Right Now

Yahoo19-05-2025

We've seen them in Dinosaur, Jurassic Park, and The Land Before Time, but how much do you really know about dinosaurs?
After speaking with paleontologist Dr. Kenneth Lacovara, I can honestly say — I didn't know as much as I thought! I mean, did you know dinosaurs likely didn't roar or that they still have living descendants today? What about the actual size of a velociraptor? There's more, too. From the speed of a T-Rex to a pterosaur's extensive wingspan, here are more fascinating dinosaur facts you probably didn't know.
For context, Dr. Lacovara has discovered some of Earth's largest dinosaurs, including the massive Dreadnoughtus from Jurassic World — he even consulted on early Jurassic films. This interview was conducted during a press trip to Mantua, New Jersey, to tour Edelman Fossil Park & Museum, which Dr. Lacovara founded and opened on March 29. It has been edited for length and clarity.
1.Velociraptors weren't as big and threatening as you think.
Universal Pictures / Via youtube.com, Helen H. Richardson/MediaNews Gr / Denver Post via Getty Images
Dr. Lacovara says, "Velociraptors are nowhere near the size they were in Jurassic Park. A velociraptor skull is about six inches — they're roughly turkey-sized. So think about velociraptor as a pissed-off turkey. The size of the velociraptor in Jurassic Park is more like the size of a dinosaur named Deinonychus, which would be a terrible thing to encounter. You would be dead quickly. They were human-sized, fast, bipedal predators, equipped with deadly sickle-shaped claws, and thanks to their specialized wrists, they could swing those claws sideways in a motion able to impale and gaff hook their prey in a single, deadly strike."
2.Hadrosaurs were EXTREMELY dangerous.
Hadrosaurs, also known as duck-billed dinosaurs, are often portrayed as friendly, approachable creatures. According to Dr. Lacovara, that's far from the truth. "Too often, they are portrayed as dopey, friendly, gentle giants. In Jurassic Park, you can walk up and pet them. In reality, they will kill you."
He adds, "There are no safe dinosaurs. Stay away from dinosaurs."
3.T-Rex had exceptionally good eyesight, despite what movies may have made you think.
T-Rex are as dangerous as they've been portrayed. "They're the largest land predators ever. They had excellent vision. They could see you if you were standing still — they could smell you, too. Scientists estimate that those grapefruit-sized eyes could spot details with up to five times the sharpness of a falcon and 13 times better than a human. And, like birds and crocs today, T-Rex could see more colors than us, with vision extending into the ultraviolet range."
"They were also fast — they could outrun the best Olympic sprinter."
4.But while you might not be able to outrun a T-Rex, you probably could out-maneuver one.
"They can't turn well. Their head and their tail are so far apart, there's a lot of angular momentum, making it hard to turn around quickly. So if you were to be confronted by a T-Rex, don't try to outrun it, try to out-maneuver it."
5.Some dinosaurs were precocial — meaning they were self-sufficient almost immediately after birth.
"Some, like titanosaurs, got up and walked away just like an antelope does today. Others gave birth to altricial babies — think a little baby robin that's totally helpless when it's born. Some dinosaurs were born like that."
6.The oldest known dinosaur is the Nyasasaurus, which lived roughly 237 million years ago.
"It lived in the Triassic period in Tanzania. It was small — maybe the size of a golden retriever. Other early dinosaurs are even smaller, more like the size of a house cat. They lived in a world dominated by crocodiles and other nasty reptilian beasts. Dinosaurs didn't become dominant until the Jurassic period, about 36 million years later."
7.Sorry, but pterosaurs are not dinosaurs.
"They're flying reptiles."
Related: 18 Adorable Celeb Pets That'll Make You Say "Awwww!"
8.Pterosaurs were the first creatures to fly that were bigger than a bug. The largest had a wingspan of 36 feet — roughly the size of a small plane.
9.It's likely that dinosaurs didn't roar — they probably grumbled or whistled.
"Dinosaurs don't roar like lions. They don't have a larynx. They have an analogous or a syrinx like birds and crocodiles. They probably made low gargles and grumbles and could have even made low whistles and pops like birds do."
10.Birds are descended from dinosaurs.
"Your children's books lied to you about pterosaurs. The only dinosaurs that have ever flown are birds." Birds evolved from dinosaurs 150 million years ago during the Jurassic Park period.
11.Troodon were among the most intelligent dinosaurs.
Paleontologists measure dinosaur intelligence using a method called the encephalization quotient, in which their brain size is compared to their body size. "Troodon, a medium-sized feathered predator that lived in modern-day North America during the Cretaceous Period, is often considered one of the brainier dinosaurs because of its high EQ. However, Dr. Lacovara notes, "It's a crude measure. What is for sure is that dinosaurs were smart enough to be dinosaurs. Organisms tend to have the brains they need."
12.Dreadnoughtus would use its massive body weight to crush prey.
Dr. Lacovara estimates Dreadnoughtus was about 65 tons. "That's nine times the weight of the T-Rex and about 10 times heavier than a Boeing 737. So you are not gonna mess with a T-Rex. Dreadnoughtus could lean against a T-Rex and press it into a tree and kill it."
Related: 21 Extremely Rare Photos That'll Change Your Perception Of The Entire World
13.But of course, not all dinosaurs existed at the same time.
For example, Dreadnoughtus didn't live at the same time as T-Rex, and T-Rex didn't exist with Stegosaurus. "Dinosaurs spanned 165 million years. Most of them never saw each other. T-Rex lived 66 million years ago and walked among the fossil bones of dinosaurs that are older than our fossils of T-Rex."
14.Many animals, including frogs, turtles, sharks, clams, and fish lived millions of years before dinosaurs.
15.And contrary to what you may have heard, oil does NOT come from them.
"Sorry, Elon Musk," Dr. Lacovara says, claiming he once got into a "Twitter fight" with Elon over whether dinosaurs produced oil. "It comes from the smallest creatures, marine plankton. There would never be enough dinosaurs in the world to make all the petroleum that we have."
16.Evidence shows velociraptors had feathers — not scales like you've seen in the movies.
Deinonychus is another dinosaur believed to have had feathers.
17.Fossilized dinosaur poop is called coprolite.
18.Some dinosaur species could swim.
"To clarify, Mosasaurs and Plesiosaurs were not dinosaurs — they were reptiles, but dinosaurs could do some swimming, just like any vertebrae animal. There are places where paleontologists have seen a dinosaur trackway that appears to be going into a lake, then the tracks become lighter and lighter until you see a few scrapes on the ground where their claws were swishing against the mud as they swam out into the lake."
19.The colors we've seen attributed to dinosaurs are completely fabricated.
"The way we assess colors is by looking at modern analogs today. So for example, what color are really giant animals today? Well, disappointingly, they're gray — from whales to hippos and rhinos. So probably the really big dinosaurs were gray or very drab."
20.Smaller dinosaurs, however, were probably very colorful.
"They could have used their color for signaling. Today, we see animals use color for threat displays, mating displays, and camouflage, of course, so there are all kinds of uses for color and pattern that dinosaurs could have used, too."
21.In 2004, paleontologists found the skull of what was believed to be a new dinosaur species. It was named Dracorex hogwartsia, a nod to the Harry Potter books, and is known for its dragon-like head. But according to Dr. Lacovara, "there's convincing research that shows that Dracorex is really just a juvenile Pachycephalosaurus."
Pachycephalosaurs have high, dome-like skulls and were first discovered around the mid-1800s. "If true, the Dracorex name would go away, and it would just be called Pachycephalosaurus."
22.Spinosaurus fossils are among the hardest to find. Paleontologists first discovered them in the early 1900s — sadly, those fossils were later destroyed in a bombing.
"The fossils were first found in 1911 in Egypt. The bones were brought to the Bavarian Museum of Natural History and were on display for decades until those bones and the bones of three other species were destroyed in April of 1944 in an Allied bombing raid. They became known as the Lost Dinosaurs of Egypt — until paleontologists found more spinosaurus fossils in Morocco in 2014." Some scientists believe they were a swimming dinosaur.
23.Dinosaurs didn't roar at their food.
"Just think – you don't walk up to your salad and yell at it before you eat it. It would have scared off prey."
24.You can't de-extinct a dinosaur.
"The de-extinction portrayed in the Jurassic movies is probably not realistic. DNA is a water-soluble molecule and doesn't seem to persist that long. The oldest DNA that's been recovered from an organism so far is about 800,000 years, and the oldest environmental DNA is less than two million years. That's a long way from 66 million years and beyond. But scientists are, through genetic engineering, bringing back species that went extinct in the very recent past, such as the dodo, the marsupial wolf, and the mammoth." In April, scientists claimed to have resurrected the dire wolf over 12,000 years after it became extinct.
25.The asteroid event that caused dinosaurs to become extinct made global surface temperatures rise as hot as a toaster or pizza oven.
"Geophysicists estimate that within an hour of impact, global surface temperatures soared to somewhere between toaster oven and pizza oven. If you were on Earth that day, exposed on the surface with nowhere to hide, you were toast." Most surviving creatures were able to burrow beneath the surface.
26.Finally, the largest creature on Earth after the asteroid event was likely badger-sized.
Were you surprised by any of these facts? Have any others to share? Write them in the comments below.
And be sure to check out Edelman Fossil Park & Museum, which features dinosaur reconstructions, live animal exhibits, a dig experience at the backyard quarry (where thousands of fossils have already been unearthed), and more!
Also in Animals: 21 Animals Mother Nature Encoded With A Secret Message

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer
Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

Yahoo

time3 days ago

  • Yahoo

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

MENLO PARK, Calif., June 04, 2025--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of senior leaders to support the company as it advances its lead investigational allogeneic T-cell immunotherapy, Orca-T®, toward potential commercial launch. Steve Gavel has joined Orca Bio as Chief Commercial Officer after most recently serving as Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech. Orca Bio has also strengthened its broader commercial organization with the addition of several senior leaders with extensive cell therapy experience to oversee Market Access, Commercial Operations and Medical Affairs. In addition to these key commercial appointments, Allison Frisbee has joined Orca Bio as a Senior Vice President, Legal, following roles at Kronos Bio, Jazz Pharmaceuticals and Bristol Myers Squibb, and as outside counsel to life science companies at Orrick, Herrington and Sutcliffe. Steve Gavel - Chief Commercial Officer Gavel brings over 30 years of experience in the biotechnology and pharmaceutical sectors, with deep expertise in the commercialization of cell and gene therapies having led strategy and execution since the earliest days of the field. "We are thrilled to welcome Steve to the Orca Bio team. Steve is a cell therapy veteran with a proven track record of building and scaling organizations in preparation for commercialization," said Nate Fernhoff, Ph.D., Co-founder and Chief Executive Officer at Orca Bio. "As we prepare for the commercial launch of Orca-T, Steve brings a perfect combination of background, experience and strategic vision to lead Orca Bio into this next phase of growth and maturation." At Legend Biotech, Gavel grew and scaled its commercial organization across multiple CAR-T therapies, including leading the successful global launch of Carvykti®, a treatment for patients with relapsed or refractory multiple myeloma. There he oversaw the global commercial development efforts including launch readiness, market access and commercial operations. Prior to Legend Biotech, Gavel led U.S. commercial strategy and development at Celgene (now Bristol Myers Squibb). Before then, he held commercial roles of increasing seniority at companies including Millennium Pharmaceuticals, IMS Health, West Pharmaceutical Services and Discovery Labs. "I'm honored to join Orca Bio as it prepares to bring its groundbreaking cell therapy to patients with high-risk blood cancers, including acute myeloid leukemia and myelodysplastic syndrome," said Steve Gavel, Chief Commercial Officer at Orca Bio. "The company's pioneering team has achieved remarkable progress, and with approximately 500 patients treated on trial to date, the potential of its novel high-precision platform is already being realized. I look forward to joining the company as we work to unlock new opportunities for growth and transform the therapeutic landscape for patients with blood cancer." Allison Frisbee - Senior Vice President, Legal Frisbee joins with strong experience as a legal and operations leader in the life science industry, with a focus on translating complex legal and regulatory challenges into clear, strategic solutions. Prior to joining Orca Bio, Frisbee served as the Chief Administrative Officer at Kronos Bio, where she oversaw a broad portfolio including Legal, HR, Facilities, IT and Compliance. Before joining Kronos, she held senior legal roles at Jazz Pharmaceuticals and Bristol Myers Squibb. "I'm thrilled to join the team at Orca Bio and help continue shaping a thoughtful, values-driven legal and compliance function," said Allison Frisbee, Senior Vice President, Legal at Orca Bio. "It's a privilege to partner with teams who are not only advancing transformative therapies, but leading with a deep commitment to integrity, accountability and an unwavering commitment to doing what's right for patients." About Orca Bio Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company's manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products designed to replace a patient's diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what's possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit Trademarks or registered trademarks used in this press release are the property of their respective owners. View source version on Contacts Corporate CommunicationsKelsey Grossmanmedia@ Investor RelationsJoshua Murrayir@

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer
Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

Business Wire

time3 days ago

  • Business Wire

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of senior leaders to support the company as it advances its lead investigational allogeneic T-cell immunotherapy, Orca-T®, toward potential commercial launch. Steve Gavel has joined Orca Bio as Chief Commercial Officer after most recently serving as Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech. Orca Bio has also strengthened its broader commercial organization with the addition of several senior leaders with extensive cell therapy experience to oversee Market Access, Commercial Operations and Medical Affairs. In addition to these key commercial appointments, Allison Frisbee has joined Orca Bio as a Senior Vice President, Legal, following roles at Kronos Bio, Jazz Pharmaceuticals and Bristol Myers Squibb, and as outside counsel to life science companies at Orrick, Herrington and Sutcliffe. Steve Gavel - Chief Commercial Officer Gavel brings over 30 years of experience in the biotechnology and pharmaceutical sectors, with deep expertise in the commercialization of cell and gene therapies having led strategy and execution since the earliest days of the field. 'We are thrilled to welcome Steve to the Orca Bio team. Steve is a cell therapy veteran with a proven track record of building and scaling organizations in preparation for commercialization,' said Nate Fernhoff, Ph.D., Co-founder and Chief Executive Officer at Orca Bio. 'As we prepare for the commercial launch of Orca-T, Steve brings a perfect combination of background, experience and strategic vision to lead Orca Bio into this next phase of growth and maturation.' At Legend Biotech, Gavel grew and scaled its commercial organization across multiple CAR-T therapies, including leading the successful global launch of Carvykti®, a treatment for patients with relapsed or refractory multiple myeloma. There he oversaw the global commercial development efforts including launch readiness, market access and commercial operations. Prior to Legend Biotech, Gavel led U.S. commercial strategy and development at Celgene (now Bristol Myers Squibb). Before then, he held commercial roles of increasing seniority at companies including Millennium Pharmaceuticals, IMS Health, West Pharmaceutical Services and Discovery Labs. 'I'm honored to join Orca Bio as it prepares to bring its groundbreaking cell therapy to patients with high-risk blood cancers, including acute myeloid leukemia and myelodysplastic syndrome,' said Steve Gavel, Chief Commercial Officer at Orca Bio. 'The company's pioneering team has achieved remarkable progress, and with approximately 500 patients treated on trial to date, the potential of its novel high-precision platform is already being realized. I look forward to joining the company as we work to unlock new opportunities for growth and transform the therapeutic landscape for patients with blood cancer.' Allison Frisbee - Senior Vice President, Legal Frisbee joins with strong experience as a legal and operations leader in the life science industry, with a focus on translating complex legal and regulatory challenges into clear, strategic solutions. Prior to joining Orca Bio, Frisbee served as the Chief Administrative Officer at Kronos Bio, where she oversaw a broad portfolio including Legal, HR, Facilities, IT and Compliance. Before joining Kronos, she held senior legal roles at Jazz Pharmaceuticals and Bristol Myers Squibb. 'I'm thrilled to join the team at Orca Bio and help continue shaping a thoughtful, values-driven legal and compliance function,' said Allison Frisbee, Senior Vice President, Legal at Orca Bio. 'It's a privilege to partner with teams who are not only advancing transformative therapies, but leading with a deep commitment to integrity, accountability and an unwavering commitment to doing what's right for patients.' About Orca Bio Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company's manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products designed to replace a patient's diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what's possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit Trademarks or registered trademarks used in this press release are the property of their respective owners.

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Yahoo

time4 days ago

  • Yahoo

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif., June 03, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) has reached an important milestone as enrollment now exceeds 75% with a total of 65 participants randomized in the study's targeted 86 participants in the six to nine year-old primary analysis population. Key Phase 3 NEAT clinical trial enrollment highlights to date include: A total of 76 participants have been enrolled, including 65 participants in the six to nine year-old primary analysis population and 11 participants aged 10 years or older. Study powering based on currently enrolled participants is approximately 80%. The rate of screening and randomization activities has materially increased with the recent activation of all study sites. A total of 108 NEAT participants have been screened to date with a low screen failure rate of 10%. All 37 NEAT participants to date have elected to transition to the NEAT open label extension (OLE) study (NCT06664853/IEDAT-04-2022). Participants who complete the full treatment period, complete study assessments, and provide informed consent are eligible to transition to the OLE study. Assuming positive study results, the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026. Quince was granted FDA Fast Track designation for the company's eDSP System for the treatment of patients with A-T based on the potential for eDSP to address a high unmet medical need. NEAT is an international, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the neurological effects of Quince's lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in autologous red blood cells; previously referred to as EryDex) in patients with A-T. Participants are randomized (1:1) between eDSP or placebo and treatment consists of six infusions scheduled once every 21 to 30 days. The primary efficacy endpoint will be measured by the change from baseline to last efficacy visit in the rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo. About Ataxia-Telangiectasia A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene, which is responsible for cell homeostatic and cell division functions including but not limited to double-stranded DNA repair. Typically, A-T is first diagnosed before the age of five as children begin to develop an altered gait and fall with greater frequency. Neurological symptoms worsen and patients with A-T frequently become wheelchair-bound by adolescence. Teenage years for patients with A-T are typically marked by repeated infections, pulmonary impairment, and malignancies. The median lifespan is approximately 25 to 30 years old with mortality due to infections and malignancy. Based on IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics information, there are approximately 4,600 diagnosed patients with A-T in the U.S. Quince estimates that there are approximately 5,000 patients with A-T in the U.K. and EU4 countries. There are currently no approved therapeutic treatments in any global market for A-T. About eDSP for A-T eDSP is comprised of dexamethasone sodium phosphate (DSP) encapsulated in a patient's own red blood cells (autologous erythrocytes). DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. The eDSP System is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic use of corticosteroid treatment. eDSP leverages Quince's proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Quince's AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube. Forward-looking Statements Statements in this news release contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as "believe," "may," "should," "expect," "anticipate," "plan," "believe," "estimated," "potential," "intend," "will," "can," "seek," or other similar words. Examples of forward-looking statements include, among others, statements relating to the timing, success, and reporting of results of the clinical trials and related data, including plans and the ability to enroll participants, impact of closing enrollment, conduct, and/or complete current and additional studies; current and future clinical development of eDSP, including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), and other potential indications; the strategic development path for eDSP; planned regulatory agency submissions, including NDAs, and clinical trials and timeline, prospects, and milestone expectations; and the potential benefits of eDSP and the company's market opportunity. Forward-looking statements are based on Quince's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled "Risk Factors" in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 13, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law. View source version on Contacts Media & Investor Contact: Stacy RoughanQuince Therapeutics, President, Corporate Communications & Investor Relationsir@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store